Evidence for systems that carry regulated work.
Source-backed reporting and analysis connected to the companies, capabilities, authorities, and operating domains it affects.
The July release carries bug fixes and sits inside a broader transition toward structured application data, new MAA forms, and mandatory PLM web-based eAF use for centrally authorised product variations.
The July package refresh adds forward-compatibility samples and revises regional vocabulary, conformance, and transmission materials for a standard FDA already accepts for new applications.
The June release expands access to structured medicinal-product data while marketing authorisation holders face staged manufacturer and pack-data enrichment deadlines.
The transition moves actor, device, certificate, and market-surveillance records from voluntary use into required EU operating workflows, increasing the cost of disconnected regulatory data.
The February guidance focuses assurance effort on software risk and confidence rather than prescribing one validation-document package, giving buyers a sharper way to examine vendor evidence and intended use.
The rule now incorporates ISO 13485:2016 by reference and replaces QSIT with a new inspection process, shifting the questions device manufacturers should ask of quality systems and evidence.
The January transition changes classification and procedure rules for post-authorisation changes, forcing regulatory operations teams to align systems, forms, content, and implementation dates.
Draft revisions to Chapter 4 and Annex 11, plus a proposed Annex 22 for artificial intelligence, signal the direction of travel—but remain consultation drafts rather than operative requirements.
